|
SG11201504038XA
(en)
|
2012-11-27 |
2015-06-29 |
Childrens Medical Center |
Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
|
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
|
RU2763795C2
(ru)
|
2014-04-23 |
2022-01-11 |
Джуно Терапьютикс, Инк. |
Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
|
|
MX375592B
(es)
|
2014-04-25 |
2025-03-06 |
The Children´S Medical Center Corp |
Composiciones y su uso para tratar hemoglobinopatias.
|
|
NZ725201A
(en)
|
2014-04-25 |
2018-05-25 |
Bluebird Bio Inc |
Improved methods for manufacturing adoptive cell therapies
|
|
LT3134432T
(lt)
*
|
2014-04-25 |
2020-04-10 |
Bluebird Bio, Inc. |
Mnd promotorius chimerinių antigenų receptoriams
|
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
AU2015357526B2
(en)
|
2014-12-05 |
2022-03-17 |
Eureka Therapeutics, Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
|
|
KR20240135036A
(ko)
|
2014-12-05 |
2024-09-10 |
메모리얼 슬로안 케터링 캔서 센터 |
B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
|
|
EA036379B1
(ru)
|
2014-12-12 |
2020-11-02 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы к bcma
|
|
EP4400516A1
(en)
|
2014-12-15 |
2024-07-17 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
EP3234120B1
(en)
|
2014-12-15 |
2025-09-03 |
The Regents of the University of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
|
EP3283520B1
(en)
|
2015-04-13 |
2020-05-06 |
Pfizer Inc |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
ES2835861T5
(en)
|
2015-05-08 |
2025-02-18 |
Childrens Medical Ct Corp |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
|
US10683369B2
(en)
|
2015-08-03 |
2020-06-16 |
Engmab Sàrl |
Monoclonal antibodies against BCMA
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
DK3368571T5
(da)
|
2015-10-30 |
2024-09-30 |
Univ California |
Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
KR20200068750A
(ko)
|
2016-04-01 |
2020-06-15 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
CN109414455B
(zh)
|
2016-04-01 |
2023-01-20 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
|
CN109415687A
(zh)
*
|
2016-04-07 |
2019-03-01 |
蓝鸟生物公司 |
嵌合抗原受体t细胞组合物
|
|
CA3029209A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
EP4282877A3
(en)
|
2016-08-10 |
2024-02-21 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
JP2019530440A
(ja)
|
2016-09-02 |
2019-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
|
|
FI4050034T3
(fi)
|
2016-09-14 |
2024-06-10 |
Teneoone Inc |
Cd3:een sitoutuvia vasta-aineita
|
|
KR20240005168A
(ko)
|
2016-11-04 |
2024-01-11 |
2세븐티 바이오, 인코포레이티드 |
항-bcma car t 세포 조성물
|
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
NZ754713A
(en)
*
|
2016-12-21 |
2025-11-28 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
|
ES3035979T3
(en)
*
|
2017-01-23 |
2025-09-11 |
Crage Medical Co Ltd |
Bcma-targeting antibody and use thereof
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
SG11201908844YA
(en)
*
|
2017-03-29 |
2019-10-30 |
Bluebird Bio Inc |
Vectors and compositions for treating hemoglobinopathies
|
|
US11261441B2
(en)
|
2017-03-29 |
2022-03-01 |
Bluebird Bio, Inc. |
Vectors and compositions for treating hemoglobinopathies
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200078404A1
(en)
|
2017-05-01 |
2020-03-12 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
US11788087B2
(en)
|
2017-05-25 |
2023-10-17 |
The Children's Medical Center Corporation |
BCL11A guide delivery
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US11427642B2
(en)
|
2017-06-20 |
2022-08-30 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
IL271194B2
(en)
|
2017-06-20 |
2024-10-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
EP3695408B1
(en)
|
2017-10-02 |
2026-01-21 |
The Broad Institute, Inc. |
Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
|
|
CN107475194B
(zh)
*
|
2017-10-09 |
2018-07-24 |
天津长和生物技术有限公司 |
Nkt细胞培养基、培养方法及二者的应用
|
|
JP7585034B2
(ja)
|
2017-10-18 |
2024-11-18 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
|
AU2018358067A1
(en)
|
2017-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
|
|
SG11202003427XA
(en)
|
2017-11-06 |
2020-05-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
SG11202004512XA
(en)
|
2017-11-15 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
JP7517983B2
(ja)
*
|
2017-11-20 |
2024-07-17 |
ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク |
非常に低レベルのｃｄ１９を発現する骨髄腫細胞を除去するｃｄ１９ｃａｒｔ細胞
|
|
BR112020010579A2
(pt)
|
2017-11-30 |
2020-11-10 |
Novartis Ag |
receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
|
|
WO2019113557A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
|
CN109971715A
(zh)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
一种扩增特异性car-t细胞的培养方法
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
US11266690B2
(en)
|
2018-02-01 |
2022-03-08 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
|
|
CN116082518A
(zh)
|
2018-02-01 |
2023-05-09 |
南京驯鹿生物技术股份有限公司 |
一种结合bcma的嵌合抗原受体（car）及其应用
|
|
CN110157675B
(zh)
*
|
2018-02-12 |
2022-05-27 |
深圳宾德生物技术有限公司 |
一种靶向性t淋巴细胞及其制备方法和应用
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
KR20200123155A
(ko)
*
|
2018-02-21 |
2020-10-28 |
셀진 코포레이션 |
Bcma-결합 항체 및 이의 용도
|
|
AU2019228128A1
(en)
|
2018-03-02 |
2020-09-03 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
EP3549597A1
(en)
*
|
2018-04-06 |
2019-10-09 |
Heinrich-Heine-Universität Düsseldorf |
Synthetic signalling constructs and its use
|
|
CN116836297A
(zh)
*
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
US12522811B2
(en)
|
2018-05-01 |
2026-01-13 |
The Children's Medical Center Corporation |
Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
|
|
US12350284B2
(en)
|
2018-05-02 |
2025-07-08 |
The Children's Medical Center Corporation |
BCL11A microRNAs for treating hemoglobinopathies
|
|
US12227763B2
(en)
|
2018-05-11 |
2025-02-18 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US20210230289A1
(en)
*
|
2018-06-12 |
2021-07-29 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12247084B2
(en)
|
2018-06-14 |
2025-03-11 |
2Seventy Bio, Inc. |
Anti-BCMA CAR antibodies, conjugates, and methods of use
|
|
CN119529091A
(zh)
*
|
2018-06-19 |
2025-02-28 |
南京传奇生物科技有限公司 |
工程化的细胞及其用途
|
|
CA3105813A1
(en)
*
|
2018-07-11 |
2020-01-16 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MD4324851T2
(ro)
*
|
2018-07-19 |
2025-12-31 |
Regeneron Pharma |
Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
|
|
WO2020033630A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
CN113474450A
(zh)
|
2018-08-09 |
2021-10-01 |
朱诺治疗学股份有限公司 |
产生工程化细胞的方法以及所述工程化细胞的组合物
|
|
EP3835320A4
(en)
|
2018-08-10 |
2022-06-01 |
Eutilex Co., Ltd. |
Chimeric antigen receptor binding to hla-dr, and car-t cell
|
|
EP3845244A4
(en)
*
|
2018-08-24 |
2022-09-07 |
Shenzhen Pregene Biopharma Co. Ltd. |
ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE
|
|
CN109134665B
(zh)
*
|
2018-08-24 |
2021-06-11 |
上海先博生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及应用
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CA3109959A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR20210055733A
(ko)
|
2018-09-07 |
2021-05-17 |
빔 테라퓨틱스, 인크. |
핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
PL3856775T3
(pl)
|
2018-09-27 |
2025-06-09 |
Autolus Limited |
Chimeryczny receptor antygenowy
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
MA54079A
(fr)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
|
|
KR20210113169A
(ko)
*
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
|
WO2020097403A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
JP2022513164A
(ja)
*
|
2018-11-30 |
2022-02-07 |
セルラリティ インク． |
胎盤由来同種ｃａｒ－ｔ細胞およびその使用
|
|
SG11202104637VA
(en)
*
|
2018-11-30 |
2021-06-29 |
Windmil Therapeutics Inc |
MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109651511B
(zh)
*
|
2018-12-26 |
2020-06-09 |
广州百暨基因科技有限公司 |
一种靶向bcma的嵌合抗原受体及其应用
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
CA3126422A1
(en)
*
|
2019-01-14 |
2020-07-23 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric receptor polypeptides and uses thereof
|
|
CN111454358A
(zh)
*
|
2019-01-18 |
2020-07-28 |
四川科伦博泰生物医药股份有限公司 |
一种嵌合抗原受体及其应用
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
IL285909B2
(en)
|
2019-03-15 |
2023-04-01 |
Cartesian Therapeutics Inc |
Single-stranded variable segments directed against bcma
|
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
CN113597328B
(zh)
|
2019-03-21 |
2025-10-31 |
瑞泽恩制药公司 |
用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
JP7776987B2
(ja)
|
2019-04-05 |
2025-11-27 |
テネオバイオ， インコーポレイテッド |
Ｐｓｍａに結合する重鎖抗体
|
|
JP7584437B2
(ja)
*
|
2019-04-05 |
2024-11-15 |
２セブンティ バイオ インコーポレイテッド |
抗ｂｃｍａ ｃａｒ ｔ細胞の製造
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
CN111850013B
(zh)
*
|
2019-06-25 |
2021-05-18 |
浙江康佰裕生物科技有限公司 |
一种共刺激受体增效的嵌合抗原受体及其应用
|
|
CN112143700B
(zh)
*
|
2019-06-26 |
2024-07-19 |
上海细胞治疗集团股份有限公司 |
制备过表达外源基因的免疫效应细胞的方法
|
|
US12544391B2
(en)
|
2019-07-16 |
2026-02-10 |
Oric Pharmaceuticals, Inc. |
CD73 inhibitors
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
AU2020334317A1
(en)
|
2019-08-16 |
2022-04-07 |
Janssen Biotech, Inc. |
Therapeutic immune cells with improved function and methods for making the same
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US20220370500A1
(en)
*
|
2019-09-18 |
2022-11-24 |
Board Of Regents, The University Of Texas System |
A method of engineering natural killer-cells to target bcma-positive tumors
|
|
JP2023501871A
(ja)
*
|
2019-09-20 |
2023-01-20 |
上海吉倍生物技術有限公司 |
Ｂｃｍａ標的化抗体及びキメラ抗原受容体
|
|
CA3149585A1
(en)
*
|
2019-09-25 |
2021-04-01 |
Bahram VALMEHR |
Multi-targeting effector cells and use thereof
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
HUE072504T2
(hu)
*
|
2019-10-30 |
2025-11-28 |
Oric Pharmaceuticals Inc |
CD73-inhibitorok
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
AU2020377930A1
(en)
|
2019-11-05 |
2022-05-19 |
Bristol-Myers Squibb Company |
Uses of anti-BCMA chimeric antigen receptors
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
CN112980886B
(zh)
*
|
2019-12-02 |
2022-02-22 |
河北森朗生物科技有限公司 |
一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用
|
|
MX2022006704A
(es)
*
|
2019-12-04 |
2022-11-09 |
Celularity Inc |
Linfocitos car-t alogenicos derivados de placenta y usos de estos.
|
|
EP4077398A4
(en)
*
|
2019-12-16 |
2024-04-10 |
Legend Biotech Ireland Limited |
SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETTING BCMA AND METHODS OF USE THEREOF
|
|
US12545746B2
(en)
|
2019-12-16 |
2026-02-10 |
2Seventy Bio, Inc. |
Anti-BCMA car antibodies, conjugates, and methods of use
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
IL295381B1
(en)
*
|
2020-02-12 |
2026-04-01 |
Juno Therapeutics Inc |
BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
|
|
JP7439279B2
(ja)
|
2020-02-13 |
2024-02-27 |
イミュノファーム テクノロジー カンパニー リミテッド |
キメラ抗原受容体の最適化
|
|
CA3167572A1
(en)
*
|
2020-02-14 |
2021-08-19 |
Robbie G. MAJZNER |
Chimeric antigen receptors with cd2 activation
|
|
KR20220146530A
(ko)
|
2020-02-27 |
2022-11-01 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포의 제조 방법
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
US12264190B2
(en)
*
|
2020-04-24 |
2025-04-01 |
Astrazeneca Ab |
Compositions and methods of treating cancer with chimeric antigen receptors
|
|
CN116157125A
(zh)
|
2020-04-28 |
2023-05-23 |
朱诺治疗学股份有限公司 |
针对bcma的t细胞疗法与免疫调节化合物的组合
|
|
CN115968300A
(zh)
*
|
2020-05-11 |
2023-04-14 |
艾宾妥斯生物公司 |
用于体内转导的载体和方法
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
GB2607514B
(en)
|
2020-07-20 |
2023-06-21 |
Enanta Pharm Inc |
Functionalized peptides as antiviral agents
|
|
CN111909271B
(zh)
*
|
2020-08-12 |
2021-03-23 |
深圳市茵冠生物科技有限公司 |
一种基于单域抗体的bcma嵌合抗原受体及其应用
|
|
US20230302155A1
(en)
|
2020-08-21 |
2023-09-28 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
CN111944850B
(zh)
*
|
2020-08-28 |
2023-03-31 |
澳门大学 |
表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
KR20230124583A
(ko)
|
2020-11-23 |
2023-08-25 |
이난타 파마슈티칼스, 인코포레이티드 |
신규한 스피로피롤리딘 유래 항바이러스제
|
|
US11352363B1
(en)
|
2020-11-23 |
2022-06-07 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
US12540141B2
(en)
|
2020-11-23 |
2026-02-03 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
US11384090B2
(en)
|
2020-11-23 |
2022-07-12 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
JP2023552773A
(ja)
|
2020-12-04 |
2023-12-19 |
セルジーン コーポレーション |
炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
|
|
US20260055430A1
(en)
*
|
2021-03-08 |
2026-02-26 |
Flagship Pioneering Innovations Vi, Llc |
Lentivirus with altered integrase activity
|
|
KR20230171994A
(ko)
|
2021-04-16 |
2023-12-21 |
셀진 코포레이션 |
선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
|
|
IL307612A
(en)
|
2021-04-16 |
2023-12-01 |
Celgene Corp |
Combined therapies with BCMA-directed T-cell therapy
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
US20250283037A1
(en)
|
2021-05-06 |
2025-09-11 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
|
US11319325B1
(en)
|
2021-05-11 |
2022-05-03 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic spiropyrrolidine derived antiviral agents
|
|
WO2022251356A1
(en)
*
|
2021-05-26 |
2022-12-01 |
Flagship Pioneering Innovations Vi, Llc |
Integrase compositions and methods
|
|
CA3225252A1
(en)
|
2021-07-14 |
2023-01-19 |
Jordan JARJOUR |
Engineered t cell receptors fused to binding domains from antibodies
|
|
US11325916B1
(en)
|
2021-07-29 |
2022-05-10 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
US11339170B1
(en)
|
2021-07-23 |
2022-05-24 |
Enanta Pharmaceuticals, Inc. |
Spiropyrrolidine derived antiviral agents
|
|
JP2024531364A
(ja)
|
2021-08-20 |
2024-08-29 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
US20230136301A1
(en)
|
2021-11-03 |
2023-05-04 |
Janssen Biotech, Inc. |
Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
|
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
|
EP4426847A4
(en)
*
|
2021-11-04 |
2026-02-25 |
Childrens Hospital Philadelphia |
Compositions and methods for the treatment of metachromatic leukodystrophy and related disorders
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
US20250382636A1
(en)
|
2022-05-26 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions for maintaining lentiviral vector and uses thereof
|
|
CA3263560A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
CN120112650A
(zh)
|
2022-10-26 |
2025-06-06 |
诺华股份有限公司 |
慢病毒配制品
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN121100267A
(zh)
|
2022-12-09 |
2025-12-09 |
朱诺治疗学股份有限公司 |
使用全息成像预测细胞表型的机器学习方法
|
|
KR20240094169A
(ko)
*
|
2022-12-13 |
2024-06-25 |
진셀비티 주식회사 |
B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
CA3278900A1
(en)
|
2023-03-31 |
2024-10-03 |
AbelZeta Inc. |
BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025109119A1
(en)
|
2023-11-22 |
2025-05-30 |
Priothera Sas |
Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025196590A1
(en)
*
|
2024-03-16 |
2025-09-25 |
Indian Institute Of Technology Bombay |
Novel anti-bcma chimeric antigen receptor, its nucleic acid sequence, and its preparation
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
CN118325927A
(zh)
*
|
2024-06-13 |
2024-07-12 |
广州安捷生物医学技术有限公司 |
编码nk细胞衔接器和car的多核苷酸及包含其的修饰细胞
|
|
WO2026006767A1
(en)
|
2024-06-28 |
2026-01-02 |
Dispatch Biotherapeutics, Inc. |
Tethered il-9/il-9r and related engineered cells and methods
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|